BioMérieux Company Top Insiders
| BMXMF Stock | USD 127.51 0.00 0.00% |
BioMérieux employs about 12.1 K people. The company is managed by 10 executives with a total tenure of roughly 53 years, averaging almost 5.0 years of service per executive, having 1208.4 employees per reported executive. Examination of BioMérieux's management performance can provide insight into the company performance.
| Alexandre Merieux CEO CEO, Director and Member of Strategy Committee |
| Guillaume Bouhours President Corporate Vice President CFO, Member of the Executive Board |
BioMérieux |
BioMérieux Management Team Effectiveness
The company has return on total asset (ROA) of 0.1008 % which means that it generated a profit of $0.1008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1751 %, meaning that it generated $0.1751 on every $100 dollars invested by stockholders. BioMérieux's management efficiency ratios could be used to measure how well BioMérieux manages its routine affairs as well as how well it operates its assets and liabilities.BioMérieux Workforce Comparison
bioMrieux SA is number one stock in number of employees category among its peers. The total workforce of Diagnostics & Research industry is currently estimated at about 403,477. BioMérieux holds roughly 12,084 in number of employees claiming about 2.99% of equities under Diagnostics & Research industry.
The company has Profit Margin (PM) of 0.16 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.21 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.21. bioMrieux SA Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. bioMrieux SA Price Series Summation is a cross summation of BioMérieux price series and its benchmark/peer.
BioMérieux Notable Stakeholders
A BioMérieux stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BioMérieux often face trade-offs trying to please all of them. BioMérieux's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BioMérieux's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Alexandre Merieux | CEO, Director and Member of Strategy Committee | Profile | |
| Guillaume Bouhours | Corporate Vice President CFO, Member of the Executive Board | Profile | |
| Pierre Boulud | Corporate Vice-President Asia-Pacific Region, Industrial Unit, Investments and Strategic Planning | Profile | |
| Yasha Mitrotti | Corporate Vice President Europe, Middle East, Africa Region, Member of the Management Committee | Profile | |
| Pierre Charbonnier | Corporate Vice President Manufacturing & Supply Chain, Member of the Management Committee | Profile | |
| Frederic Beseme | Head CSR | Profile | |
| Franois Lacoste | Ex RD | Profile | |
| Mark Miller | Member of the Management Committee, Chief Medical Officer and Head of Regulatory Affairs | Profile | |
| Valerie Leylde | Communications HR | Profile | |
| Sylvain Morgeau | Head of Investor Relations | Profile |
About BioMérieux Management Performance
The success or failure of an entity such as bioMrieux SA often depends on how effective the management is. BioMérieux management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioMérieux management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioMérieux management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
bioMrieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as B-D Mrieux. bioMrieux S.A. was founded in 1963 and is headquartered in Marcy lEtoile, France. bioMrieux S.A. is a subsidiary of Institut Mrieux SA. Biomerieux operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 12084 people.
BioMérieux Workforce Analysis
Traditionally, organizations such as BioMérieux use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BioMérieux within its industry.BioMérieux Manpower Efficiency
Return on BioMérieux Manpower
| Revenue Per Employee | 279.4K | |
| Revenue Per Executive | 337.6M | |
| Net Income Per Employee | 49.7K | |
| Net Income Per Executive | 60.1M | |
| Working Capital Per Employee | 34.1K | |
| Working Capital Per Executive | 41.2M |
Complementary Tools for BioMérieux Pink Sheet analysis
When running BioMérieux's price analysis, check to measure BioMérieux's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioMérieux is operating at the current time. Most of BioMérieux's value examination focuses on studying past and present price action to predict the probability of BioMérieux's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioMérieux's price. Additionally, you may evaluate how the addition of BioMérieux to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |